Therefore, therapeutically targeting COX-2 and fibronectin in EGFR-stimulated HNSCC metastasis would be of interest because metastasis represents the main clinical challenge after primary tumor resection. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.